tlooto
Sign up

65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC

S. Peters, D. Tan, D.E. Gerber, J. Urbanic, S. Ramalingam, J. Yu, L. Xing, A. Rittmeyer, T. Ciuleanu, J. Menezes, H.R. Kim, C. Rojas, K. Syrigos, H. Hayashi, A. Haridass, S. Bordenave, R. Nathani, G. Pudussery, L. Yang, D. de Ruysscher

2024.12.1Immuno-Oncology and Technology

DOI: 10.1016/j.iotech.2024.100808

Abstract

Abstract is not available.

Citation format

PETERS, S., et al. 65O checkmate 73l: Phase III study comparing nivolumab (n) + concurrent chemoradiotherapy (CCRT) followed by n ± ipilimumab (i) v CCRT followed by durvalumab (d) for previously untreated, locally advanced stage (stg) III NSCLC. Immuno-Oncology and Technology, 2024.